Comment from Frakes Kyle

Summary: Kyle Frakes, Founder of Moonlight Longevity, supports the inclusion of Delta Sleep-Inducing Peptide (DSIP) on the Section 503A Bulk Drug Substances List. He argues that DSIP has a history of clinical promise for treating opioid withdrawal and sleep disorders, addressing a critical unmet need in the opioid crisis.